Innate Pharma S.A. (IPHA)
Innate Pharma S.A. Statistics
Share Statistics
Innate Pharma S.A. has 83.81M shares outstanding. The number of shares has increased by 3.54% in one year.
| Shares Outstanding | 83.81M |
| Shares Change (YoY) | 3.54% |
| Shares Change (QoQ) | 1.24% |
| Owned by Institutions (%) | 0.17% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,293 |
| FTD / Avg. Volume | 0.56% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -28.15 and the forward PE ratio is 2.91. Innate Pharma S.A.'s PEG ratio is 0.3.
| PE Ratio | -28.15 |
| Forward PE | 2.91 |
| PS Ratio | 4.11 |
| Forward PS | 1.1 |
| PB Ratio | 4.11 |
| P/FCF Ratio | -6.1 |
| PEG Ratio | 0.3 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Innate Pharma S.A..
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.73, with a Debt / Equity ratio of 0.77.
| Current Ratio | 3.73 |
| Quick Ratio | 3.73 |
| Debt / Equity | 0.77 |
| Debt / EBITDA | -21.69 |
| Debt / FCF | -1.14 |
| Interest Coverage | -19.8 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $286,745.86 |
| Profits Per Employee | $-41,823.2 |
| Employee Count | 181 |
| Asset Turnover | 0.28 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -9.05% in the last 52 weeks. The beta is 0.95, so Innate Pharma S.A.'s price volatility has been higher than the market average.
| Beta | 0.95 |
| 52-Week Price Change | -9.05% |
| 50-Day Moving Average | 2.01 |
| 200-Day Moving Average | 2 |
| Relative Strength Index (RSI) | 65.36 |
| Average Volume (20 Days) | 232,736 |
Income Statement
In the last 12 months, Innate Pharma S.A. had revenue of 51.9M and earned -7.57M in profits. Earnings per share was -0.09.
| Revenue | 51.9M |
| Gross Profit | -4.12M |
| Operating Income | -12.67M |
| Net Income | -7.57M |
| EBITDA | -1.84M |
| EBIT | -6.93M |
| Earnings Per Share (EPS) | -0.09 |
Balance Sheet
The company has 70.61M in cash and 39.89M in debt, giving a net cash position of 30.71M.
| Cash & Cash Equivalents | 70.61M |
| Total Debt | 39.89M |
| Net Cash | 30.71M |
| Retained Earnings | -336.89M |
| Total Assets | 151.5M |
| Working Capital | 73.37M |
Cash Flow
In the last 12 months, operating cash flow was -32.56M and capital expenditures -2.35M, giving a free cash flow of -34.91M.
| Operating Cash Flow | -32.56M |
| Capital Expenditures | -2.35M |
| Free Cash Flow | -34.91M |
| FCF Per Share | -0.42 |
Margins
Gross margin is -7.94%, with operating and profit margins of -24.41% and -14.59%.
| Gross Margin | -7.94% |
| Operating Margin | -24.41% |
| Pretax Margin | -14.59% |
| Profit Margin | -14.59% |
| EBITDA Margin | -3.54% |
| EBIT Margin | -24.41% |
| FCF Margin | -67.26% |
Dividends & Yields
IPHA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for IPHA is $11, which is 397.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $11 |
| Price Target Difference | 397.7% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | -3.78 |
| Piotroski F-Score | 3 |